684 patents
Page 4 of 35
Utility
Stabilized Receptor Polypeptides and Uses Thereof
21 Sep 23
The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11.
Jeonghoon SUN, Lei-Ting Tony TAM, Mark Leo MICHAELS, Thomas Charles BOONE, Rohini R. DESHPANDE, Yue-Sheng LI, Huiquan HAN
Filed: 7 Jun 23
Utility
Easy Open Apparatus for Medicament Storage Carton
21 Sep 23
A carton for medicament storage includes a bottom box and a lid.
Trevor Raymond Lowe, Joshua Merilos, Scott J. Gerondale, Lrr Thompson, Harrison North, Jeffrey Burmeister, Alexander Rentschler, Brian McGonigle
Filed: 2 Sep 21
Utility
Heterocyclic Compounds As Triggering Receptor Expressed on Myeloid Cells 2 Agonists and Methods of Use
21 Sep 23
Lara C. CZABANIUK, Timothy Hopper, Jonathan B. Houze, Jane Panteleev, Gwenaella Rescourio, Vincent Santora, Haoxuan Wang, Ryan D. White, Alice R. Wong, Yongwei Wu, Maxence Bos, John Mancuso, Ivan Franzoni
Filed: 30 Nov 22
Utility
Heterocyclic Compounds As Triggering Receptor Expressed on Myeloid Cells 2 Agonists and Methods of Use
21 Sep 23
Lara C. CZABANIUK, Timothy HOPPER, Jonathan B. HOUZE, Jane PANTELEEV, Gwenaella RESCOURIO, Vincent SANTORA, Haoxuan WANG, Ryan D. WHITE, Alice R. WONG, Yongwei WU, Maxence BOS, John MANCUSO, Ivan FRANZONI
Filed: 30 Nov 22
Utility
Cell Culture Media and Methods of Making and Using the Same
14 Sep 23
Presented herein are methods for preparing and treating mammalian cell culture media through the addition of low levels of poloxamer and nanofiltration.
Nicholas MARCHAND, Glen BOLTON, Sara Ann GALL, Jian WU
Filed: 27 Jul 21
Utility
Rnai Constructs for Inhibiting HSD17B13 Expression and Methods of Use Thereof
7 Sep 23
The present invention relates to RNAi constructs for reducing expression of the HSD17B13 gene.
Daniel C. H. LIN, Michael OLLMANN, Justin K. MURRAY, Bradley J. HERBERICH, Amrita DAS, Patrick COLLINS, Oliver HOMANN
Filed: 3 Jun 21
Utility
Formulations Of Apremilast
7 Sep 23
Provided herein are oral dosage forms comprising a) a core tablet comprising (i) a drug layer comprising apremilast and hypromellose acetate succinate (HPMCAS) in an amorphous solid dispersion; and (ii) a swellable layer comprising one or more swellable polymers; and b) a coating layer disposed on the core tablet, wherein the oral dosage form surface comprises at least one drug release orifice.
Nathan Bennette, William Brett Caldwell, Christi Hostetler, Kazden Ingram, Dory King, Kyle Kyburz, Alison Viles
Filed: 12 May 23
Utility
Drug Delivery Device Assembly and Accessory for Drug Delivery Device
7 Sep 23
A drug delivery device assembly is provided, including an injector housing, a needle assembly, a drive assembly, and a reflective surface.
Carsten Bech, Jakob Halkjaer Pedersen, Joshua Jay Dudman, Adrianus Gerardus Verschuren, Chiushun Dan
Filed: 1 Nov 21
Utility
Hybrid Predictive Modeling for Control of Cell Culture
7 Sep 23
A method of controlling a cell culture process uses hybrid predictive modeling in a model predictive controller.
Mohammad Rashedi, Hamid Khodabandehlou, Seyedehmina Rafieishishavan, Matthew N. Demers, Aditya Tulsyan, Tony Y. Wang
Filed: 24 Feb 23
Utility
Assessment of Cleaning Procedures of a Biotherapeutic Manufacturing Process
31 Aug 23
Provided herein are methods of assessing or validating a cleaning procedure of a biotherapeutic manufacturing process, said method comprising analyzing by a surface plasmon resonance (SPR)-based assay the binding activity of a cleaned sample to a ligand which binds to a biotherapeutic produced by the manufacturing process.
Rammahipal KOUDA
Filed: 3 Jun 21
Utility
Rotationally Biased Insertion Mechanism for a Drug Delivery Pump
31 Aug 23
An insertion mechanism for a drug pump includes an insertion mechanism housing; a sleeve; a rotational biasing member initially held in an energized state; a retraction biasing member and a hub connected to a proximal end of a needle, wherein the retraction biasing member is held initially in an energized state between the hub and the sleeve.
Mark A. Destefano, Lawton Laurence, John C. Love, Ian B. Hanson, Paul F. Bente, IV
Filed: 8 May 23
Utility
Compounds That Inhibit MCL-1 Protein
31 Aug 23
BRIAN S. LUCAS, NICK A. PARAS
Filed: 8 May 23
Utility
CD3 Binding Antibodies
31 Aug 23
The present invention relates to human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.
Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Katherine Harris, Duy Pham
Filed: 3 Oct 22
Utility
Predictive Modeling and Control of Cell Culture
31 Aug 23
A method of controlling a cell culture process includes, for each time interval of one or more time intervals during the cell culture process, obtaining current values of one or more cell culture attributes associated with a cell culture, predicting one or more future values of a particular cell culture attribute associated with the cell culture, and controlling one or more physical inputs to the cell culture process.
Hamid Khodabandehlou, Tony Y. Wang, Aditya Tulsyan
Filed: 22 Sep 21
Utility
Antibody Constructs for FLT3 and CD3
31 Aug 23
The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human FLT3 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell.
Tobias Raum, Claudia Blümel, Franziska Bott, Christoph Dahlhoff, Patrick Hoffmann, Elisabeth Nahrwold, Jochen Pendzialek
Filed: 19 Jul 22
Utility
Multi-specific Antibodies Binding to Bcma
17 Aug 23
Multi-specific, human heavy chain antibodies (e.g., UniAbs™) binding to BCMA are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat disorders that are characterized by the expression of BCMA.
Nathan Trinklein, Katherine Harris, Harbani Malik, Ute Schellenberger, Omid Vafa, Shelley Force Aldred
Filed: 30 Jun 21
Utility
Methods for Increasing Mannose Content of Recombinant Proteins
10 Aug 23
The present invention relates to methods of upregulating the high mannose glycoform content of a recombinant protein during a mammalian cell culture by manipulating the mannose to total hexose ratio in the cell culture media formulation.
Chung-Jr HUANG, Xiaoming YANG
Filed: 13 Apr 23
Utility
Dosing Regimen of Kras G12C Inhibitor
10 Aug 23
Provided herein are methods of administering a KRAS G12C inhibitor to a cancer subject.
Haby HENARY, James Russell LIPFORD, Victor J. CEE
Filed: 21 Apr 23
Utility
Drug Delivery Device with Gear Module and Related Method of Assembly
3 Aug 23
Drug delivery devices and related methods of assembly are disclosed.
Jerome Olivas, Guojie Song, Sudeshna Dutta Ray
Filed: 8 Mar 23
Utility
Heavy Chain Antibodies Binding to Psma
3 Aug 23
Anti-PSMA heavy chain antibodies (e.g., UniAbs™) are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat disorders that are characterized by the expression of PSMA.
Wim van Schooten, Starlynn Clarke, Kevin Dang, Ben Buelow
Filed: 3 Feb 23